Abstract:Macroautophagy/autophagy is an evolutionarily conserved pathway responsible for clearing cytosolic aggregated proteins, damaged organelles or invading microorganisms. Dysfunctional autophagy leads to pathological accumulation of the cargo, which has been linked to a range of human diseases, including neurodegenerative diseases, infectious and autoimmune diseases and various forms of cancer. Cumulative work in animal models, application of genetic tools and pharmacologically active compounds, has suggested the potential therapeutic value of autophagy modulation in disease, as diverse as Huntington, Salmonella infection, or pancreatic cancer. Autophagy activation versus inhibition strategies are being explored, while the role of autophagy in pathophysiology is being studied in parallel. However, the progress of preclinical and clinical development of autophagy modulators has been greatly hampered by the paucity of selective pharmacological agents and biomarkers to dissect their precise impact on various forms of autophagy and cellular responses. Here, we summarize established and new strategies in autophagy-related drug discovery and indicate a path toward establishing a more efficient discovery of autophagy-selective pharmacological agents. With this knowledge at hand, modern concepts for therapeutic exploitation of autophagy might become more plausible.Abbreviations: ALS: amyotrophic lateral sclerosis; AMPK: AMP-activated protein kinase; ATG: autophagy-related gene; AUTAC: autophagy-targeting chimera; CNS: central nervous system; CQ: chloroquine; GABARAP: gamma-aminobutyric acid type A receptor-associated protein; HCQ: hydroxychloroquine; LYTAC: lysosome targeting chimera; MAP1LC3/LC3: microtubule associated protein 1 light chain 3; MTOR: mechanistic target of rapamycin kinase; NDD: neurodegenerative disease; PDAC: pancreatic ductal adenocarcinoma; PE: phosphatidylethanolamine; PIK3C3/VPS34: phosphatidylinositol 3-kinase catalytic subunit type 3; PtdIns3K: class III phosphatidylinositol 3-kinase; PtdIns3P: phosphatidylinositol 3-phosphate; PROTAC: proteolysis-targeting chimera; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2; SQSTM1/p62: sequestosome 1; ULK1: unc-51 like autophagy activating kinase 1.

Targeting autophagy with small-molecule activators for potential therapeutic purposes

Targeting selective autophagy and beyond: From underlying mechanisms to potential therapies

Targeting autophagy drug discovery: Targets, indications and development trends

Inhibition of Autophagy by a Small Molecule Through Covalent Modification of the LC3 Protein

Small‐Molecule Regulators of Autophagy and Their Potential Therapeutic Applications

Targeting autophagy in disease: established and new strategies

Autophagy Regulators As Potential Cancer Therapeutic Agents: A Review

Drug discovery by targeting the protein‒protein interactions involved in autophagy

Autophagy Intertwines with Different Diseases—Recent Strategies for Therapeutic Approaches

Molecular Modulators and Receptors of Selective Autophagy: Disease Implication and Identification Strategies

Manipulating Autophagic Degradation in Human Diseases: from Mechanisms to Interventions

Synthetic Activators of Autophagy

Targeting autophagy using small-molecule compounds to improve potential therapy of Parkinson's disease

Targeting Autophagy to Overcome Human Diseases

The Participation of Non-Canonical Autophagic Proteins in the Autophagy Process and Their Potential As Therapeutic Targets

Targeting selective autophagy in CNS disorders by small-molecule compounds

Mechanisms of autophagy and relevant small-molecule compounds for targeted cancer therapy

Pharmaceutical Agents for Targeting Autophagy and Their Applications in Clinics

Targeting Autophagy for the Treatment of Liver Diseases

Small-Molecule Regulators Of Autophagy As Potential Anti-Cancer Therapy

Epigenetic and post-translational modifications in autophagy: biological functions and therapeutic targets